Cite
HARVARD Citation
Kato, K. et al. (n.d.). P-052A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress. Annals of oncology. p. . [Online].